Generalized pustular psoriasis (GPP) is a rare sometimes lethal form of psoriasis, caused by series of mutations in the interleukin-36 receptor antagonist (IL-36RA) gene associated with its reduced expression or activity. Administration of exogenous IL-36RA can be a potent therapeutic approach to treatment of GPP and other forms of psoriasis. Since cleavage of the starting N-formylmethionine residue from N-terminal end is needed for full biological activity of IL-36RA we have developed technology for producing IL-36RA lacking N-formylmethionine residue in Escherichia coli. We have created a series of plasmids carrying the E. coli methionine aminopeptidase (MAP) gene under the control of different promoters for co-expression of IL-36RA and MAP and tested their effect on IL-36RA production. The highest production of IL-36RA with <3 % of unprocessed molecules with uncleaved N-terminal formylmethionine residue has been shown for E. coli strain carrying the MAP gene under the control of arabinose-inducible promoter.